SCHEDULE 13G: L1 Capital Global Opportunities Master Fund Discloses Significant 9.99% Stake in AEON Biopharma

L1 Capital Global Opportunities Master Fund, Ltd. has disclosed a 9.99% beneficial ownership stake in AEON Biopharma, Inc., comprising Class A Common Stock and warrants.

Summary

• L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G, indicating beneficial ownership in AEON Biopharma, Inc.
• The fund beneficially owns 8,960,000 shares of AEON Biopharma, Inc. Class A Common Stock, representing 9.99% of the outstanding class.
• This ownership includes 6,000,000 shares of Class A Common Stock and 2,960,000 Class A Warrants.
• The percentage of ownership is calculated based on 89,627,288 Class A Common Stock outstanding immediately after an offering, as detailed in the Issuer's Prospectus Supplement filed on January 6, 2025.
• The filing explicitly states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of AEON Biopharma, Inc.
• David Feldman and Joel Arber, Directors of L1 Capital Global Opportunities Master Fund, Ltd., may be deemed to beneficially own these securities but disclaim beneficial ownership for all other purposes.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing an ownership stake, which is inherently neutral in tone. However, the disclosure of a significant institutional investment can be interpreted as a positive signal by the market.

Positives

• A major institutional investor, L1 Capital Global Opportunities Master Fund, Ltd., has taken a significant 9.99% stake in AEON Biopharma, Inc., which can be interpreted as a vote of confidence in the company's prospects.

Risks

• The beneficial ownership of L1 Capital Global Opportunities Master Fund, Ltd. is subject to a 9.99% limitation, which excludes 3,040,000 Class A Warrants and 6,000,000 Class B Warrants from the current beneficial ownership calculation, potentially limiting their immediate ability to fully exercise all their warrant holdings if it would exceed this threshold.

Future Outlook

This Schedule 13G filing by L1 Capital Global Opportunities Master Fund, Ltd. does not contain forward-looking statements or guidance from AEON Biopharma, Inc. It solely discloses the beneficial ownership stake of the reporting person.

Industry Context

The disclosure of a significant stake by an institutional investor like L1 Capital Global Opportunities Master Fund in a biopharma company such as AEON Biopharma is a common occurrence in the sector, reflecting ongoing investment interest in companies with potential for growth and innovation. Such investments can signal market confidence in the company's pipeline or strategic direction, aligning with broader trends of capital allocation towards promising life sciences ventures.

Stakeholder Impact

• Shareholders may view the significant stake by L1 Capital Global Opportunities Master Fund, Ltd. as a positive indicator of institutional confidence in AEON Biopharma, Inc.

Key Dates

Recommendation

Keywords

AEON Biopharma, L1 Capital Global Opportunities Master Fund, Schedule 13G, institutional ownership, Class A Common Stock, warrants, biopharma investment, equity stake, SEC filing